CITATION:
Tentori F. Mineral and bone disorder and outcomes in hemodialysis patients: Results from the DOPPS. Semin Dial 2010; 23(1): 10-14
ABSTRACT:
In recent years, increasing attention has been paid to
the role of nonclassical risk factors in the development
and progression of cardiovascular disease among
patients with chronic kidney disease (CKD). The metabolic
changes that characterize CKD mineral and bone
disorder (MBD) have been associated with increased
cardiovascular calcification (1–3) and arterial dysfunction
(4,5), which in turn appear to contribute to higher
morbidity and mortality (6,7). The National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
guidelines have indicated that therapeutic regimens
aimed at normalization of mineral bone disorder markers
may improve outcomes of CKD patients (8). A similar
approach was also endorsed by the recently
published Kidney Disease Improving Global Outcomes
guidelines (KDIGO) (9). The detailed data collected in
the Dialysis Outcomes and Practice Patterns Study
(DOPPS) across 12 countries over a 13-year period have
led to a large number of publications in the area of
CKD-MBD (10–16). In the current report, we summarize
the most recent DOPPS findings on this topic,
specifically regarding [1] trends in serum levels of MBD
markers, [2] the association of MBD markers with
mortality risk, and [3] insights into the relationship of
vitaminDtherapy to clinical outcomes.
|
|
The DOPPS Annual Report
The DOPPS Annual Report portrays descriptive statistics for multiple, representative cross-sectional cohorts over several practice areas, from anemia to vascular access.
|
DOPPS Presentations of Published Research
|
|
Coordinated by research scientists
and staff of Arbor Research Collaborative
for Health, and supported by research grants from Amgen (since 1996),
Kyowa Hakko Kirin (since 1999, in Japan), Genzyme (since 2009), and Abbott (since 2009) without
restrictions on publications.
|
|